Microdeletion syndrome

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, August 18, 2022 - 9:30pm

Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 365,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
  • The stock options were granted on August 17, 2022 at an exercise price of $2.15 per share, which is equal to the closing price of Geron common stock on the date of grant.
  • The options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Gerons 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies.

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, August 12, 2022 - 9:05pm

Research and Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2022 were $8.1 million compared to $5.2 million for the corresponding quarter in 2021.

Key Points: 
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2022 were $8.1 million compared to $5.2 million for the corresponding quarter in 2021.
  • If any of these risks materialize or Jasper Therapeutics assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.
  • There may be additional risks that Jasper Therapeutics does not presently know, or that Jasper Therapeutics currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements.
  • While Jasper Therapeutics may elect to update these forward-looking statements at some point in the future, Jasper Therapeutics specifically disclaims any obligation to do so.

Geron Corporation Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022 - 9:05pm

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the second quarter of 2022 and key upcoming expected milestones.
  • Assuming positive top-line results, U.S. and EU regulatory submissions are also planned in the first and second half of 2023, respectively.
  • ET on Thursday, August 11, 2022 to review recent events and second quarter 2022 financial results.
  • Geron encourages investors to carefully consider the Companys results under GAAP, as well as the supplemental non-GAAP financial information, to more fully understand Gerons business.

Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022 - 9:05pm

- Oral fadraciclib demonstrated good tolerability with continuous dosing;

Key Points: 
  • - Oral fadraciclib demonstrated good tolerability with continuous dosing;
    - Conference call scheduled for August 10, 2022 at 4:30 pm ET -
    BERKELEY HEIGHTS, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced second quarter 2022 financial results and provided a business update.
  • In the second half of 2022 we are optimizing the dosing schedule to maximize target coverage and determine recommended Phase 2 dose (RP2D).
  • Tax credit receipts of $3.3 million in respect of the financial year ended December 31, 2021, were received in April 2022.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

Channel Medsystems Announces Publication of Long-term Clinical Outcomes with Cerene® Cryotherapy for the Treatment of Heavy Menstrual Bleeding

Retrieved on: 
Wednesday, August 10, 2022 - 7:43pm

The manuscript, entitled The Cerene Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding: 36-Month Outcomes from The CLARITY Study, is available on the International Journal of Womens Health website .

Key Points: 
  • The manuscript, entitled The Cerene Cryotherapy Device for the Treatment of Heavy Menstrual Bleeding: 36-Month Outcomes from The CLARITY Study, is available on the International Journal of Womens Health website .
  • The CLARITY study was a prospective, multi-center, single-arm, open-label study that evaluated 242 premenopausal women who underwent cryoablation with Cerene.
  • At 36 months, 85% of patients were satisfied or very satisfied and 91% would definitely or maybe recommend Cerene.
  • Cerene is an in-office endometrial cryoablation treatment that safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia.

Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics

Retrieved on: 
Wednesday, August 10, 2022 - 6:05pm

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.

Key Points: 
  • Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.
  • Disc is building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.
  • Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.
  • Disc has a clinical-stage development pipeline composed of investigational product candidates that affect heme biosynthesis and iron metabolism.

DevOps Institute Releases First Ever 'Global SRE Pulse 2022' Report

Retrieved on: 
Tuesday, August 9, 2022 - 2:04pm

LEHIGH ACRES, Fla., Aug. 9, 2022 /PRNewswire/ -- DevOps Institute, a global learning community that empowers the people who power IT, today announced the release of the inaugural "Global SRE Pulse 2022" report. SRE Pulse offers thorough insights into the state, practices, health activities, automation and adoption of SRE across the globe. The report includes input from more than 460 SRE leaders and practitioners from companies of all sizes to provide a detailed and accurate snapshot of the current state of SRE.

Key Points: 
  • SRE Pulse offers thorough insights into the state, practices, health activities, automation and adoption of SRE across the globe.
  • "The Global SRE Pulse examines the human and automation aspects of SRE and offers deep insights into SRE adoption, best practices, challenges and outcomes.
  • Research and data analysis for Global SRE Pulse was led by DevOps Institute's chief research officer, Eveline Oehrlich, with support from sponsors Sumo Logic, AWS, StackState and Sedai.
  • "The Global SRE Pulse shares promising findings around SRE adoption and the benefits of improving system reliability," said Oehrlich.

DevOps Institute Releases First Ever 'Global SRE Pulse 2022' Report

Retrieved on: 
Tuesday, August 9, 2022 - 2:04pm

LEHIGH ACRES, Fla., Aug. 9, 2022 /PRNewswire/ -- DevOps Institute, a global learning community that empowers the people who power IT, today announced the release of the inaugural "Global SRE Pulse 2022" report. SRE Pulse offers thorough insights into the state, practices, health activities, automation and adoption of SRE across the globe. The report includes input from more than 460 SRE leaders and practitioners from companies of all sizes to provide a detailed and accurate snapshot of the current state of SRE.

Key Points: 
  • SRE Pulse offers thorough insights into the state, practices, health activities, automation and adoption of SRE across the globe.
  • "The Global SRE Pulse examines the human and automation aspects of SRE and offers deep insights into SRE adoption, best practices, challenges and outcomes.
  • Research and data analysis for Global SRE Pulse was led by DevOps Institute's chief research officer, Eveline Oehrlich, with support from sponsors Sumo Logic, AWS, StackState and Sedai.
  • "The Global SRE Pulse shares promising findings around SRE adoption and the benefits of improving system reliability," said Oehrlich.

MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:01pm

ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.

Key Points: 
  • ROCKVILLE, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June30, 2022.
  • We made important progress in the second quarter, during which we completed enrollment in a Phase 1/2 dose expansion study of lorigerlimab, a PD-1 CTLA-4 DART molecule.
  • Recent progress and anticipated events in 2022 related to MacroGenics investigational product candidates in clinical development are highlighted below.
  • Revenue for the quarter ended June30, 2022 included MARGENZA net sales of $4.7 million, compared to $3.2million for the quarter ended June30, 2021.

FibroGen Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:01pm

2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021

Key Points: 
  • 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021
    SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the companys recent developments.
  • Second quarter total roxadustat net sales in China1 by FibroGen and the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca was $53.1 million, compared to $52.8 million in the second quarter of 2021.
  • Total revenue for the second quarter of 2022 was $29.8 million, as compared to $24.4 million for the second quarter of 2021.
  • FibroGen will host a conference call and webcast today, Monday, August 8, 2022, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update.